Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cubist Pharmaceuticals Inc. Announces Exclusive Option to Acquire Illumigen Biosciences
Tuesday October 16, 4:17 pm ET
Lead Compound IB657 Would Address Unmet Medical Need in HCV Infections;
Cubist Will Pay $4.7 Million for Option and Will Fund the Pivotal IND Enabling Study
LEXINGTON, Mass. & SEATTLE--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST ) and Illumigen Biosciences, Inc. announced today that they have signed an agreement under which Cubist has an exclusive option to acquire Illumigen on terms that have been agreed to by the parties. For the option, Cubist will pay $4.7 Million and also will pay approximately $1 Million for an IND-enabling study of Illumigen's lead compound, IB657, and for Illumigen's operating costs during the option period. IB657 is a protein therapeutic in late-stage pre-clinical development as an interferon replacement product for the treatment of Hepatitis C virus (HCV) infections.
Mike Bonney, President and CEO of Cubist, said "This option provides us with an opportunity to immediately leverage our antiinfective development and regulatory expertise. The unmet medical need which IB657 would address represents a substantial market opportunity. If we exercise our option, adding an HCV compound will be an important step as we develop a pipeline behind our successful IV antibiotic CUBICIN."
Donald Elmer, Chairman of Illumigen, said "IB657 holds great promise as a therapy that may offer improved safety and efficacy when compared with current standard of care. We believe Cubist is ideally positioned to move the IB657 program forward."
If Cubist exercises its option to acquire Illumigen, Cubist will pay Illumigen shareholders $9 Million upfront and up to $75.5 Million in HCV development and regulatory milestones. If Cubist develops an Illumigen product for the treatment of viral infections other than HCV, additional development and regulatory milestone payments of up to $117 Million would apply. If Illumigen product(s) are commercialized, sales milestones of up to $140 Million as well as tiered royalties would apply.
...About IB657
IB657 is a late-stage pre-clinical protein therapeutic being developed as an interferon replacement. IB657 activates a key antiviral pathway downstream from the point of interferon activation. This pathway is responsible for much of the antiviral activity of interferon. IB657 does not activate the broad range of cellular functions induced by interferon. IB657 is therefore predicted to produce the antiviral activity of interferon but to have fewer side effects. The primary clinical indication targeted for IB657 is treatment of HCV infection. However, based on the proposed mechanism of action, IB657 may have therapeutic utility in the treatment of certain other viral diseases. Pre-clinical studies to assess activity against these viruses may occur in parallel with its development for HCV infection.
About Illumigen
Illumigen Biosciences, Inc. was co-founded by Drs. Charles Magness and Shawn Iadonato in 2000 to discover beneficial human genetic mutations that might provide a roadmap for novel therapeutic drug mechanisms. The discovery of IB-657 resulted from an investigation into the cause of apparent immunity to HCV infection enjoyed by people with a specific naturally occurring genetic mutation. Prior to founding Illumigen, Drs. Magness and Iadonato both were involved in the Human Genome Project. Illumigen is a privately held biopharmaceutical company based in Seattle, WA. Additional information can be found at Illumigen's web site at www.illumigen.com.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes pre-clinical programs that address unmet medical need in Gram-positive infections, Gram-negative infections, and CDAD (Clostridium difficile-associated diarrhea). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
<<
EXTO P & D-
Exit Only Inc. Hits US Used Car Market!
EXIT ONLY INC
E X T O
Price: $ 0.43
EXTO launched its first site for online used car marketing in Canada
back in May, with shocking results. The incredible response of the
Canadian launch is expected to be far surpassed as this hits the US
market. Their fee structure is like nothing else on the market. Free
listings, no hidden costs, and best of all pay only for interested
buyers lead info. This is the edge that will make this company blow the
market away. Huge news hit on this today as the company announced they
are tested and ready to release the US launch. Don't waste time, once
the new site hits the market, it will take off. Move on EXTO ASAP!
Thanks-I thought the pps increase was due to Zacks forecast but looks as if this is the reason.
Zacks earnings preview-CBST:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23719003
Zacks earnings preview-CBST:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23719003
Zacks Earnings Preview: Allstate, Citigroup, Continental Airlines, Cubist Pharmaceuticals and Intel
10:18a ET October 15, 2007 (Business Wire)
Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes Allstate (NYSE: ALL), Continental Airlines (NYSE: CAL), Cubist Pharmaceuticals (Nasdaq: CBST) and Intel (Nasdaq: INTC). To see more earnings analysis, visit http://at.zacks.com/?id=3207.
Earnings Preview is written by Charles Rotblut, CFA, Senior Market Analyst for Zacks.com.
Calling for new record highs seems rather trivial these days with the Dow holding above 14,000, but it is very possible that the blue-chip average's ascent could continue.
The third full week of October will be highlighted by reports from 12 Dow components.
At least one brokerage analyst has raised his quarterly profit forecast within the past week on five of the 12 companies. In addition, nine out of the 12 companies topped second-quarter expectations. Finally, although expectations have been worsening for Citigroup (NYSE: C), it is possible that the market could withstand a weak report and downbeat conference call from the financial conglomerate.
Of course, there will be more than just these 12 Dow members reporting. In total, we have confirmed earnings reports from 268 companies, 83 of which are S&P 500 members. Large-cap stocks will dominate the earnings calendar for the next 14 days, followed by multiple reports from mid- and small-cap companies.
Friday is an options expiration day. It is also the anniversary of the 1987 crash.
The New York Fed's manufacturing index, published on Monday, will be the week's first economic report. Tuesday features September industrial production and capacity utilization and the National Association of Homebuilders' October housing index. September CPI and housing starts will be released on Wednesday. Thursday will bring the Conference Board's September Leading Indicators index and the October Phili Fed survey. No economic reports are scheduled for Friday.
Third-Quarter Earnings Performance
As of Thursday evening, 75 companies within the S&P 1500 (S&P 500, S&P Midcap 400 and S&P SmallCap 600) had reported earnings. This is hardly a large enough sample to draw any conclusions from, but for those of who are curious, positive surprises are leading negative surprises by a margin of 1.6:1. Median company growth is running at 9.5%. The growth rate is within the range I would expect for the entire earnings season, though I do expect a higher proportion of positive surprises as earnings season goes on. (The ratio could temporarily worsen over the next week given that multiple banks are scheduled to report.)
Companies That Could Issue Positive Earnings Surprises during the Week of Oct 15 - 19
As I discussed in last Wednesday's Industry Rank Analysis column, brokerage analysts have been raising forecasts on multiple property and casualty insurers recently, including Allstate (NYSE: ALL). The lack of a major hurricane striking the U.S. this year, the rebound in the financial markets and higher premiums are all likely behind the bullishness. In the specific case of ALL, roughly one-third of the covering analysts have raised their third-quarter profit projections during the past two weeks. The revisions have resulted in a 11-cent increase in the consensus estimate to $1.65 per share. The most accurate estimate is even more bullish at $1.75 per share. Investors should be aware, however, that over the past four quarters, this insurer has missed expectations two times and topped expectations two times. Allstate is scheduled to report on Thursday, Oct 18, before the start of trading.
Despite the adverse affect of high fuel prices, Continental Airlines (NYSE: CAL) is expected to report good third-quarter earnings. The airline achieved record load factors in September and estimates that it achieved an increase in consolidated revenue per available seat mile of between 4.5% and 5.5%. (Load factor measures how full a plane is; the higher the load factor is, the more likely the plane is going to feel cramped.) The bullish September numbers caused three of the 10 covering brokerage analysts to raise their third-quarter forecasts. The consensus earnings estimate of $2.12 per share is 10 cents above the average forecast of a month ago. The most accurate estimate is more bullish at $2.16 per share. CAL has topped expectations for four consecutive quarters. Continental Airlines is scheduled to report on Thursday, Oct 18, before the start of trading.
Cubist Pharmaceuticals (Nasdaq: CBST) has topped expectations three times during the past four quarters. Ahead of the company's third-quarter report, one of the covering brokerage analysts raised his profit forecast. Although the revision was not significant enough to move the consensus estimate from 25 cents per share, it did result in a most accurate estimate of 29 cents per share. Cubist Pharmaceutical is scheduled to report on Wednesday, Oct 17, after the close of trading.
Although the aggregate outlook for semiconductor earnings is not too bright this quarter, Intel (Nasdaq: INTC) is likely to be a notable standout. The company is projected to have earned 31 cents per share versus 21 cents a year ago. The third-quarter consensus estimate has risen by a penny during the past four weeks, reflecting positive revisions by five brokerage analysts. The leading chipmaker has topped expectations twice during the past four quarters and matched expectations twice. Intel is scheduled to report on Tuesday, Oct 16, after the close of trading.
Want to turn earnings surprises into quick profits? Learn how by visiting http://at.zacks.com/?id=3206.
About the Zacks Rank
http://www.goerie.com/apps/pbcs.dll/article?AID=/20071015/LIFESTYLES06/710150321/-1/LIFESTYLES21
DEAR DR. GOTT: In a recent column, you recommended switching from Fosamax to Evista for the treatment of osteoporosis because of the possible complication of mandibular necrosis.
I would like to know if you would recommend it for someone who has been in remission from Hodgkin's for 10 years. The chemo treatment has caused early menopause and osteopenia.
I would appreciate your advice on this issue. Your column in a valuable tool, and my family appreciates your recommendations as well as your willingness to accept the success of alternative treatments. We hope to continue reading it for a long time.
DEAR READER: I am less enthusiastic about Evista after having learned of recent studies showing that the drug can cause premature heart disease in some women. Discuss this issue with your gynecologist. I'm not aware of any connection between Hodgkin's disease and Evista, but follow up on this with your doctor as well. As far as I'm concerned, Evista should be put on the back shelf until the complications of therapy are understood fully.
Are you talking about the pps?
Yep sally, you are so right. The SEC does appreciate tips from the public. FYI, they do not receive a tip and act on it the next day,month, or year in most cases. Also FYI, you might be interested in this little SEC action among many others.
How long have you been "investing" in pinkies?
http://investorshub.advfn.com/boards/read_msg.asp?message_id=18652343
Yes it is, for the lying SLJB stock manipulators!
Thanks couch, I just forwarded your repost of the original lies to the SEC/OSC just in case they have lost or forgotten them.
More scammers today:
PPYH Changes To A Fast Track.
Physical Property Holdings Inc.
PPYH
$0.25
Last week Physical restructured and changed the focus of the company to
pursue HK Real Estate. Their acquisitions are already making news as
they sweep through the HK market with there target list. Monday will be
a big day for this one, get your broker on it as the trading warms up.
Its nothing like the boot he and other lying pumpers will get from the OSC IMO.
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7:00a ET October 12, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated enrollment of the pivotal trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL).
The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and BioCryst which was granted earlier this year. The study will evaluate the rate of objective responses in patients enrolled at sites in the United States, Europe, and Australia. Eligible patients are those with CTCL of Stages IB through IVA who have disease that is persistent, progressive or recurrent during or after treatment with at least three systemic therapies. The study's primary endpoint is to determine the objective response rate, defined as either complete response or partial cutaneous response that is sustained for at least 28 days. Secondary endpoints include assessing the safety and tolerability of extended daily treatment with oral forodesine HCL, assessment of the time to objective response and the duration of objective response.
"We are very excited that this pivotal study of forodesine HCL in CTCL has begun," said Philip P. Breitfeld, M.D., Executive Director, Oncology Development and Associate Chief Medical Officer of BioCryst. "Based on the encouraging results we saw in an earlier study, we believe that this pivotal trial should provide data to establish forodesine HCL as a new treatment alternative for CTCL patients who have not responded to currently available therapies."
"Initiation of this pivotal trial is a great step forward toward our goal of getting our late-stage pipeline products to market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.
Forodesine HCL is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). In addition to CTCL, the drug is currently being studied in clinical trials for indications including T and B- cell leukemia (T-ALL, B-ALL), and chronic lymphocytic leukemia (CLL).
About BioCryst
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23635581
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7:00a ET October 12, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated enrollment of the pivotal trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL).
The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and BioCryst which was granted earlier this year. The study will evaluate the rate of objective responses in patients enrolled at sites in the United States, Europe, and Australia. Eligible patients are those with CTCL of Stages IB through IVA who have disease that is persistent, progressive or recurrent during or after treatment with at least three systemic therapies. The study's primary endpoint is to determine the objective response rate, defined as either complete response or partial cutaneous response that is sustained for at least 28 days. Secondary endpoints include assessing the safety and tolerability of extended daily treatment with oral forodesine HCL, assessment of the time to objective response and the duration of objective response.
"We are very excited that this pivotal study of forodesine HCL in CTCL has begun," said Philip P. Breitfeld, M.D., Executive Director, Oncology Development and Associate Chief Medical Officer of BioCryst. "Based on the encouraging results we saw in an earlier study, we believe that this pivotal trial should provide data to establish forodesine HCL as a new treatment alternative for CTCL patients who have not responded to currently available therapies."
"Initiation of this pivotal trial is a great step forward toward our goal of getting our late-stage pipeline products to market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.
Forodesine HCL is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). In addition to CTCL, the drug is currently being studied in clinical trials for indications including T and B- cell leukemia (T-ALL, B-ALL), and chronic lymphocytic leukemia (CLL).
About BioCryst
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23635581
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7:00a ET October 12, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated enrollment of the pivotal trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL).
The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and BioCryst which was granted earlier this year. The study will evaluate the rate of objective responses in patients enrolled at sites in the United States, Europe, and Australia. Eligible patients are those with CTCL of Stages IB through IVA who have disease that is persistent, progressive or recurrent during or after treatment with at least three systemic therapies. The study's primary endpoint is to determine the objective response rate, defined as either complete response or partial cutaneous response that is sustained for at least 28 days. Secondary endpoints include assessing the safety and tolerability of extended daily treatment with oral forodesine HCL, assessment of the time to objective response and the duration of objective response.
"We are very excited that this pivotal study of forodesine HCL in CTCL has begun," said Philip P. Breitfeld, M.D., Executive Director, Oncology Development and Associate Chief Medical Officer of BioCryst. "Based on the encouraging results we saw in an earlier study, we believe that this pivotal trial should provide data to establish forodesine HCL as a new treatment alternative for CTCL patients who have not responded to currently available therapies."
"Initiation of this pivotal trial is a great step forward toward our goal of getting our late-stage pipeline products to market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.
Forodesine HCL is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). In addition to CTCL, the drug is currently being studied in clinical trials for indications including T and B- cell leukemia (T-ALL, B-ALL), and chronic lymphocytic leukemia (CLL).
About BioCryst
Actually, I am with Ameriturd.
I for one, am tired of waiting for these jerks to convert my shares.
The brains of PBLS management were handcuffed long ago!
Were they scammed or are they just dumb as rocks? Or, is it they are scammers themselves as someone has mentioned?
Ca use in osteoarthritis:
http://www.ismni.org/jmni/pdf/21/12MANICOURT.pdf
Press Release Source: North-West Oil Group
North West Oil Group Inc. to Open New York Office
Thursday October 11, 7:39 am ET
Company to Establish American Presence in Financial Epicenter With Strategically Located Manhattan Office
MOSCOW--(MARKET WIRE)--Oct 11, 2007 -- North-West Oil Group Inc. (Other OTC:NWOL.PK - News) today announced that it has signed a lease for its new US-based representative office located in the center of Manhattan in New York city.
The office will be run by executives from Russia putting the company closer to the epicenter of the US financial markets and is expected to be fully operational by month end.
Mr. Malyshev, President of North West Oil Group Inc. (Other OTC:NWOL.PK - News) stated, "We're very excited to be opening our New York office, establishing an important physical presence in the United States. This calculated step strategically puts us in the heart of US financial markets, the financial community and most importantly in very close proximity to our shareholders. As we continue to focus on executing our business plan, it is expected that our accessibility to the US capital markets will play a pivotal role in further promoting corporate transparency, strengthening our ability to qualify for a new exchange listing and bettering our direct access to US institutional investors."
Mr. Malyshev further stated, "As promised in our press release dated October 9th, it remains our intention to release the independent valuation report of 100% of shares of OOO 'North West Oil Group - Saratov' as early as next week."
About North West Oil Group, Inc.
North West Oil Group Inc. is a publicly traded Oil & Gas company trading under the ticker symbol "NWOL" on the U.S. Pinksheets market.
So do I!
SEC Email: enforcement@sec.gov
Pinksheets.com Email: info@pinksheets.com; issuerservices@pinksheets.com
UCE Email: spam@uce.gov
FBI Web site: http://www.fbi.gov
DOJ Web site: http://www.usdoj.gov (Dept of Justice)
The Jay ne Carroll Show is a political talk radio program that airs daily in the Portland , Oregon , metropolitan area. Carroll asked her audience to come up with an official name for the Clinton $1.7 million house in Chappaqua , New York . Carroll's call-in contest required the names to be in relative good taste, to be original, and to capture the essence of one or both of the Clintons . The response was overwhelming! Some names nominated for the Clinton 's home included:
Perjurers' Palace
HillBilly Villa
The House of Bill's Repute
Drawers Downs
Cheatem Estates
Sin Simeon
The Knee Pad
The White Trash House
The Blight House
The Panderosa
Liars' Lair
Bill & Hill's Bribe & Breakfast
The Clinton Compost
Dogpatch on the Hudson
The Hen House
The Out House
The Love Shack
The House of Seven Felonies
Motel Sex
But the clear, hands-down winner was--
DISGRACELAND
New bird flu strain dangerous to humans
http://www.sciencedaily.com/upi/index.php?feed=Science&article=UPI-1-20071007-17441600-bc-britai....
LONDON, Oct. 7 (UPI) -- A new strain of the bird flu virus spreading around the world is more infectious to humans, a study lead by a U.S. researcher has found.
Led by Yoshihiro Kawaoka of the University of Wisconsin-Madison, the new study found the H5N1 virus has apparently mutated into a new strain that increases the risk of a human pandemic due to its increased level of communicability, The Independent said Saturday.
Kawaoka said the new strain does not represent a fully pandemic strain of the virus, but warned the mutated virus has been found in both Europe and Africa.
"The viruses circulating in Europe and Africa all have this mutation," the doctor said. "So they are the ones that are closer to human-like flu."
Since the virus was first reported in 2003, 329 people worldwide have been infected according to World Health Organization figures.
Those figures also show that of those infected during that time period, 201 have died as a result.
The British newspaper said health groups worldwide have prepared for a possible pandemic by collecting anti-flu drugs and preparing emergency treatment plans.
"The older you are---", wow, I have a chance,lol.
I was out of town and missed it.
Is the new Stalin,er, Putins govt. good for investment?
Posted on Sat, Oct. 06, 2007 10:15 PM
By ROBERT R. AMSTERDAM
Amsterdam & Peroff law firm
LONDON | Foreign investors are increasingly wondering whether investing in Russia is worth the risks.
As recently as 2003, Russia was a promising emerging market. Yet in the last four years, alarm bells have been ringing so often and so loudly that the most likely response of most foreign investors will be to seek opportunities elsewhere.
On one hand there are the success stories — those investors who have made a fast buck on the ballooning Russian stock markets and those companies that have staked out a solid and growing market share in an increasingly affluent Russia.
Yet on the other hand, there are the recurring headlines — about illegal expropriations, the imprisonment or deportation of entrepreneurs, mistrials, show trials and contract killings.
In Russia, law has become an instrument of the increasingly hubristic and corrupt political elite. Today’s Kremlin disregards laws with impunity while simultaneously using legal pretexts such as tax or environmental regulations to obtain what it wants. From the OECD to the World Bank to Transparency International and Freedom House, every statistic and register lends support to the view that Russia is the most thoroughly corrupt among major powers in the world today.
Take tax law. Imposing tax liability is one of the Kremlin’s favored means of pressuring businesses to do its bidding. The law — let alone economic rationality — is irrelevant.
To this day, the Kremlin stands behind the tax bills imposed on the Yukos Oil Co., including the 2004 tax assessment that drove the company into bankruptcy.
To break up and repossess Yukos Oil and to justify jailing CEO Mikhail Khodorkovsky, the company was charged $8 of tax per $1 of revenue in 2004. The company collapsed, and billions of dollars of shareholder value evaporated.
The Kremlin also tears up business deals at will — even huge investment agreements with foreign companies that have poured billions of dollars into Russia. These companies are put in a chokehold until they surrender whatever it is that the Kremlin is after. No one is above the extortion tactics of the Kremlin — whether it is Shell, BP, PwC or the next sorry victim of the Kremlin’s selective application and misapplication of laws.
Moreover, the corruption is viral, with people across the country beginning to follow the example of the men behind the Kremlin’s red brick walls. While the Kremlin has its hand in every sector considered politically strategic, like energy, it has left other sectors alone. Yet those sectors have other challenges to worry about because of the pervasive corruption that trickles down from the political leadership.
With government and the justice system in severe disrepute, the market and the rule of law have lost out to a free-for-all. The Kremlin does not seem to care enough about the reputational costs of the manner in which it treats investors and it should not be surprised to find that foreign investors no longer want to take risks in Russia.
What is particularly unfortunate is that in such a climate, Russia’s own people have been betrayed by their leadership. Both entrepreneurs and the rest of the populace have been and will continue to be the first victims of foreign investors’ decisions to seek better investment conditions elsewhere.
Whether Russia’s leadership will wake up to the country’s true market potential is an open question. There is still hope for that potential to be unlocked, not by thievery but by real economic fundamentals. For the time being, however, the Russian leadership has a long way to go to win the confidence of foreign investors.
©2007 Robert R. Amsterdam
Robert R. Amsterdam is founding partner of the law firm Amsterdam & Peroff. He is international defense counsel for jailed Yukos CEO Mikhail B. Khodorkovsky.
http://www.kansascity.com/273/story/306393.html
Pandemic: Bird Flu
This is a film about what will happen when the flu pandemic takes hold. An accurate account of a global disaster that the world's governments have foreseen, and are expecting at any moment.
http://science.discovery.com/tv-schedules/special.html?paid=48.15158.25405.0.0
NanoViricides Treatments Proven Superior in Testing; Results Released at International Conference
posted Wednesday, 3 October 2007
MN1 Staff Writer
WEST HAVEN, Conn. (October 3, 2007) - NanoViricides Inc. (OTCBB: NNVC) recently presented important results regarding the company's FluCide-I and FluCide-HP treatments for influenzas.
Dr. Eugene Seymour, MD, MPH, CEO of the company commented at the 5th International Bird Flu Conference in Las Vegas: "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic."
NanoViricides is on the cutting edge of the battle against these influenzas, and representatives from Vietnam, Indonesia, and Turkey have made it clear to the company that no good treatment options exist currently.
Seymour relayed their sentiments in his presentation at the conference: "These speakers complained that patients sought medical care too late for Tamiflu - the drug currently recommended by the World Health Organization - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."
Included in the company's research results were findings that the improved FluCide-I is now 16X (1,600 percent) better than oseltamivir (active ingredient of TamiFlu), and FluCide-HP is 8X (800 percent) better than oseltamivir, based on dose-response comparisons.
NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.
The company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin America, and has already crossed the border into the U.S.
NanoViricides is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.
http://feeds.mn1.com/nanoviricides_treatments_proven_superior_in_testing_results.htm
I think I paid around $1/mask but I bought 100 at a time for all my family members. I am not sure but think the original NanoMask is on hold until FDA decides something. AFAIK there is no recall-I have all of my originals.
The owner of the website below (google NanoMask for other distrs) posted on the RB EMFP thread a couple of years ago.
http://2hdistributors.com/
Attn: All governments ruled by Allah!
1. Anyone remember the Convocation Ceremony at Virginia Tech following the slaughter of their students from one of their own and the strong Muslim presence / representation of the Muslim faith on the campus?
2. Isn't Barack Obama a Muslim?
***********************************************************************************************
Allah or Jesus? By Rick Mathes,
The Muslim religion is the fastest growing religion per capita in The United States, especially in the minority races!!!
Last month I attended my annual training session that's required for maintaining my state prison security clearance.
During the training session there was a presentation by three Speakers representing the Roman Catholic, Protestant and Muslim faiths, who explained each of their beliefs.
I was particularly interested in what the Islamic Imam had to Say. The Imam gave a great presentation of the basics of Islam, complete with a video. After the presentations, time was provided for questions and answers.
When it was my turn, I directed my question to the Imam and asked: "Please, correct me if I'm wrong but I understand that most Imams and clerics of Islam have declared a holy jihad [Holy war] against the infidels of the world and, that by killing an infidel, (which is a command to all Muslims) they are assured of a place in heaven.
If that's the case, can you give me the definition of an Infidel?"
There was no disagreement with my statements and, without Hesitation, he replied, "Non-believers!"
I responded, "So, let me make sure I have this straight. All followers of Allah have been commanded to kill everyone who is not of Your Faith so they can have a place in Heaven. Is that correct?"
The expression on his face changed from one of authority and Command to that of "a little boy who had just been caught with his hand in the cookie jar."
He sheepishly replied, "Yes."
I then stated, "Well, sir, I have a real problem trying to imagine Pope John Paul commanding all Catholics to kill those of your faith or Dr. Stanley ordering all Protestants to do the same in order to guarantee them a place in Heaven, the Imam was speechless.
I continued, "I also have problem with being your 'friend' when you and your brother clerics are telling your followers to kill me! Let me ask you a question. Would you rather have your Allah, who tells you to kill me in order for you to go to Heaven, or my Jesus who tells me to love you because I am going to Heaven and He wants you to be there with me?"
You could have heard a pin drop as the Imam hung his head in shame.
Needless to say, the organizers and/or promoters of the 'Diversification' training seminar were not happy with Rick's way of dealing with The Islamic Imam and exposing the truth about the Muslims' beliefs.
In twenty years there will be enough Muslim voters in the U.S. To Elect the President!
I think everyone in the US should be required to read this but with the liberal justice system, liberal media, and the ACLU, there is no Way this will be widely publicized.
Please pass this on to all your e-mail contacts. This is a true Story and the author, Rick Mathes, is a well known leader in prison Ministry.
How have the "lyin" pumpers worked these two statements?
I ordered several dozen a year or so back before the FDA jumped on them for more testing. If I remember correctly, the big concern was what the filter nanoparticles would do when/if they were inhaled into the lungs.
My thinking is I had rather have nanoparticles from filter in my lungs rather than birdflu (particles).
Thanks techkim but I just C & P what I find,lol.
September 28, 2007 - 5:00 AM EST
EMFP 0.23 0.025
Today 5d 1m 3m 1y 5y 10y
Emergency Filtration Products Issues FDA Update
Emergency Filtration Products, Inc. (EFP) (PINKSHEETS: EMFP) today announced that it has withdrawn the Company's 510(k) notification (510(k)) for its NanoMask product from current FDA review. EFP originally filed its initial 510(k) in 2006. The FDA review had been suspended pending EFP response to various FDA requests for additional information, some of which required the company to commission additional scientific testing. The deadline for responding to the FDA requests is October 5, 2007. However, EFP learned recently that the required testing will not be completed by that time.
EFP management believes that the company has made substantial progress in 2007 toward completing all of the additional scientific testing necessary to respond to the FDA information request. EFP in conjunction with Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), the company with which EFP has announced a merger, has initiated all required testing and analyses. EFP has also retained well-known scientific and medical experts to ensure thorough scientific response to the FDA's information request. ANI has been assisting the funding of the ongoing testing and expects to continue to assist funding EFP to enable EFP to finalize the required testing in order to resubmit a 510(k) notification.
EFP intends to submit a new 510(k) notification as soon as the company is satisfied that all of the information requested by FDA staff is available and is scientifically sound. The schedule for completion of all required testing and preparation of a new FDA notification is imprecise due to the nature of the testing required. However, management currently estimates that a complete new 510(k) notification will be ready for submission to FDA around the middle of December.
"EFP's initial 510(k) submission to the FDA, which was made by the Company's former management, gave rise to significant comments by the FDA," said Philip Dascher, CEO, EFP. "As a result, EFP, in tandem with ANI, had to develop new testing protocols and perform testing at independent laboratories in order to satisfactorily answer the FDA's comments. Since we are braving new ground, working with emerging technologies, we have had to originate new ways of testing our product -- which have been reviewed by the FDA -- in order to verify its safety and effectiveness. This process has taken considerably more time than originally anticipated, but we expect to complete our testing and file a new 510(k) with the FDA before the end of the year if possible. Obviously, we want to complete the current testing and file our new FDA notification as soon as we possibly can. However, we will not rush this filing or the underlying scientific testing and analyses. We will file again with FDA just as soon as we are confident that we can provide all of the information they requested with a first-rate scientific basis."
For further information about Emergency Filtration Products, please visit:
www.emergencyfiltration.com
Safe Harbor Statement
This release may contain statements that are forward looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP and AN do not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the companies could differ significantly from such forward-looking statements.
Contact:
Philippe Niemetz
800-477-7570
or
212-344-6464
p.niemetz@panconsultants.com
Source: Market Wire (September 28, 2007 - 5:00 AM EST)
News by QuoteMedia
www.quotemedia.c
This is a product first promoted during the bird flu excitement a couple of years ago. I made money (.70-1.20) and bought masks,on EMFP but FDA stepped in and placed new requirements on them.
September 28, 2007 - 5:00 AM EST
EMFP 0.23 0.025
Today 5d 1m 3m 1y 5y 10y
Emergency Filtration Products Issues FDA Update
Emergency Filtration Products, Inc. (EFP) (PINKSHEETS: EMFP) today announced that it has withdrawn the Company's 510(k) notification (510(k)) for its NanoMask product from current FDA review. EFP originally filed its initial 510(k) in 2006. The FDA review had been suspended pending EFP response to various FDA requests for additional information, some of which required the company to commission additional scientific testing. The deadline for responding to the FDA requests is October 5, 2007. However, EFP learned recently that the required testing will not be completed by that time.
EFP management believes that the company has made substantial progress in 2007 toward completing all of the additional scientific testing necessary to respond to the FDA information request. EFP in conjunction with Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), the company with which EFP has announced a merger, has initiated all required testing and analyses. EFP has also retained well-known scientific and medical experts to ensure thorough scientific response to the FDA's information request. ANI has been assisting the funding of the ongoing testing and expects to continue to assist funding EFP to enable EFP to finalize the required testing in order to resubmit a 510(k) notification.
EFP intends to submit a new 510(k) notification as soon as the company is satisfied that all of the information requested by FDA staff is available and is scientifically sound. The schedule for completion of all required testing and preparation of a new FDA notification is imprecise due to the nature of the testing required. However, management currently estimates that a complete new 510(k) notification will be ready for submission to FDA around the middle of December.
"EFP's initial 510(k) submission to the FDA, which was made by the Company's former management, gave rise to significant comments by the FDA," said Philip Dascher, CEO, EFP. "As a result, EFP, in tandem with ANI, had to develop new testing protocols and perform testing at independent laboratories in order to satisfactorily answer the FDA's comments. Since we are braving new ground, working with emerging technologies, we have had to originate new ways of testing our product -- which have been reviewed by the FDA -- in order to verify its safety and effectiveness. This process has taken considerably more time than originally anticipated, but we expect to complete our testing and file a new 510(k) with the FDA before the end of the year if possible. Obviously, we want to complete the current testing and file our new FDA notification as soon as we possibly can. However, we will not rush this filing or the underlying scientific testing and analyses. We will file again with FDA just as soon as we are confident that we can provide all of the information they requested with a first-rate scientific basis."
For further information about Emergency Filtration Products, please visit:
www.emergencyfiltration.com
Safe Harbor Statement
This release may contain statements that are forward looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP and AN do not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the companies could differ significantly from such forward-looking statements.
Contact:
Philippe Niemetz
800-477-7570
or
212-344-6464
p.niemetz@panconsultants.com
Source: Market Wire (September 28, 2007 - 5:00 AM EST)
News by QuoteMedia
www.quotemedia.c
You got it Loki. Either a few who are ignorant of scams or attempting to manipulate the pps by lies. The SEC is watching them though (the liars):)